Acurx Pharmaceuticals, Inc.
ACXP
$0.33
-$0.029-8.08%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.96M | 1.62M | 2.30M | 2.82M | 3.17M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.78M | 2.82M | 4.12M | 4.38M | 5.11M |
| Operating Income | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M |
| Income Before Tax | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M |
| EBIT | -2.78M | -2.82M | -4.12M | -4.38M | -5.11M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.16 | -0.17 | -0.26 | -0.28 | -0.37 |
| Normalized Basic EPS | -0.10 | -0.11 | -0.16 | -0.18 | -0.23 |
| EPS Diluted | -0.16 | -0.17 | -0.26 | -0.28 | -0.37 |
| Normalized Diluted EPS | -0.10 | -0.11 | -0.16 | -0.18 | -0.23 |
| Average Basic Shares Outstanding | 16.93M | 16.36M | 15.82M | 15.47M | 13.84M |
| Average Diluted Shares Outstanding | 16.93M | 16.36M | 15.82M | 15.47M | 13.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
